SOURCES SOUGHT
A -- In Vitro Assessments for Antimicrobial Activity
- Notice Date
- 3/17/2009
- Notice Type
- Sources Sought
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Office of Acquisitions, 6700 B Rockledge Room 3214 MSC7612, Bethesda, Maryland, 20892-7612
- ZIP Code
- 20892-7612
- Solicitation Number
- SS-NIAID-DMID-NIHAI2009066
- Archive Date
- 4/16/2009
- Point of Contact
- Harry L Brubaker,, Phone: 301-443-2966, Yvette R Brown,, Phone: 301-496-0612
- E-Mail Address
-
brubakerh@mail.nih.gov, ybrown@niaid.nih.gov
- Small Business Set-Aside
- N/A
- Description
- Sources Sought Notice Information Introduction THIS NOTICE IS FOR INFORMATION AND PLANNING PURPOSES ONLY. THIS IS NOT A REQUEST FOR PROPOSAL(S) AND DOES NOT COMMIT THE GOVERNMENT TO AWARD A CONTRACT NOW OR IN THE FUTURE. NO SOLICITATION IS AVAILABLE AT THIS TIME. BASED ON CAPABILITY STATEMENTS RECEIVED IN RESPONSE TO THIS SOURCES SOUGHT ANNOUNCEMENT, THIS ACQUISITION MAY BE SOLICITED AS A 100% SMALL BUSINESS SET-ASIDE. ALL SMALL BUSINESS ORGANIZATIONS (SB, SDB, WOSB, HUBZone, VOSB, and SDVOSB) ARE ENCOURAGED TO RESPOND TO THIS NOTICE. SMALL BUSINESS ORGANIZATIONS MUST HAVE THEIR SIZE STATUS CERTIFIED BY THE SMALL BUSINESS ADMINISTRATION. ALL SMALL BUSINESSES ARE ENCOURAGED TO RESPOND. THE NAICS CODE IS 541711 WITH A SIZE STANDARD OF 500 EMPLOYEES. Description NIAID’s role in developing medical products to counter emerging, re-emerging and other infectious diseases, as well as agents of bioterrorism, is part of a larger national strategy, involving multiple governmental agencies. As such, NIAID supports integrated efforts in basic and applied research, product development, and technology development based on national priorities for medical products. Since 2001, NIAID has established a comprehensive infrastructure with extensive resources that support all levels of biodefense research. With this solid framework of research and product development resources for biodefense in place, NIAID is now transitioning this infrastructure to provide the flexibility required to meet the challenges of emerging, re-emerging and other infectious diseases in addition to biodefense. The use of in vitro assays helps advance our understanding of infectious diseases as well as the development of therapeutics and vaccines. Therefore, the Division of Microbiology and Infectious Diseases (DMID) is committed to developing and providing in vitro assays to benefit the research community and public health. For the most part, in vitro assay services and other research resources are currently provided through multiple, specialized programs. DMID now seeks to adopt an integrated approach to the provision of services and resources by creating unified, comprehensive, coordinated programs. This strategy is being employed to: advance science by promoting cross-fertilization across and within disciplines and approaches; serve the research community more conveniently; achieve efficient use of resources through economy of scale and avoidance of duplication; and provide the flexibility needed to respond to changing priorities. Accordingly, DMID is establishing the In Vitro Assessments for Antimicrobial Activity program, which will utilize the Indefinite Delivery, Indefinite Quantity (IDIQ) contract mechanism. Under IDIQ contracts, base contract awards are made to multiple offerors that successfully propose a general approach to the technical requirements of the solicitation, providing a guaranteed minimum award. Task orders for specific tasks requiring specialized expertise are solicited and funded within the program Contractor pool. DMID is replacing multiple pathogen or class specific solicitations with one broad IDIQ solicitation for multiple contracts to cover all areas of current and potential future interests. The work under this acquisition has been broken into five Parts. Work under Parts A, B and D require Biosafety Levels (BSL) 1 through 3, and compliance with Select Agent Regulations through the Centers for Disease Control (CDC) and/or the United States Department of Agriculture (USDA) (42 CFR Part 73, 7 CFR Part 331, and/or 9 CFR Part 121). 1.Part A – Bacteria and Fungi – Will support the development and use of in vitro assays for routine screening of products against a wide range of bacterial and fungal pathogens, to include all bacteria and fungi on the NIAID Category A, B and C Priority Pathogens list (http://www3.niaid.nih.gov/topics/BiodefenseRelated/Biodefense/research/CatA.htm) and other bacterial and fungal pathogens that cause disease in humans. 2.Part B - Viruses – Will support the development and use of in vitro assays for routine screening products against a wide range of viral pathogens, to include all viruses on the NIAID Category A, B and C Priority Pathogens list, and other viral pathogens that cause disease in humans. 3.Part C – Parasites and Vectors – Will support the development and use of in vitro assays for routine screening of products against a wide range of parasitic pathogens, to include all parasites and vectors on the NIAID Category A, B and C Priority Pathogens list, and other parasitic pathogens that cause disease in humans. This Part also includes screening against cell lines from insect and other arthropod vectors. 4.Part D - Toxins – Will support the development and use of in vitro assays for routine screening of products against a wide range of toxins, to include all toxins on the NIAID Category A, B, and C Priority Pathogens list. 5.Part E – Central Data Management Center – Will support the development, implementation, operation, and maintenance of a central data management system to support all activities conducted under Parts A, B, C and D. In order to qualify for work under Part E, Contractors must also qualify for one or more of Parts A-D. For the purposes of this acquisition: •Assays – in vitro procedures for determining the concentration, purity, and/or biological activity of a substance by measuring its effect on an organism, tissue, cell, enzyme or receptor preparation. •Products – broadly defined and include therapeutic substances targeting the host or the pathogen. •Pathogens – bacteria, viruses, parasites, toxins and fungi, including NIAID Category A, B and C Priority Pathogens. •Toxins – microbial toxins as they relate to human disease, and other toxins on the NIAID Category A, B and C Priority Pathogens list (http://www3.niaid.nih.gov/topics/BiodefenseRelated/Biodefense/research/CatA.htm). •Vectors – insects or other arthropods that carry pathogens from infected to uninfected hosts. •Pathogens of interest – must be pathogens which cause disease in humans; however surrogate human pathogens may be used for diseases where human pathogens cannot be studied. •Reagents – biochemical, genomic, molecular, cellular, and immunologic materials integral to research on these pathogens, toxins and vectors. Capability statements submitted as a result of this announcement should demonstrate the offerors’ qualifications and experience, specifically providing evidence as to their capability to perform this requirement, with particular attention to the following: Technical Capability: adequacy and appropriateness of the general technical approach to in vitro assays, to include protocol and assay development; technical approach to production and characterization of pathogens and quality control strains. Personnel and Project Management: adequacy, appropriateness and relevance of expertise, experience, qualifications, and availability of the key professional and technical staff with a project of similar size, scope, and complexity; adequacy and appropriateness of proposed organization and staffing to ensure efficient planning, initiation, implementation, conduct, and completion of all activities, including plans for communication and sharing of research resources. Facilities, Equipment and other Resources: availability of adequate facilities, with biocontainment appropriate for the pathogens proposed, including at least BSL1 through BSL3; availability of equipment necessary for the proposed studies; adequacy of institutional biosafety program; and capabilities for the receipt, storage, shipping and inventory of products, pathogens, specimens, and reagents. Past Performance: Past performance is considered essential. In addition to demonstrating that they have met the above qualifications, interested parties must identify at least three other projects of similar size and complexity. All capable small business organizations are encouraged to submit capability statements based on this announcement. Interested organizations should submit two copies of their capability statement addressing each of the areas cited above. Any proprietary information should be so marked. Written capability statements should be received by the Contracting Officer by April 1, 2009. Please reference the solicitation number on all related correspondence. No collect calls will be accepted. Facsimile and e-mail transmissions will be accepted. Any proprietary information should be so marked.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=f1a12903447e6ce4e9dbdfbf29e825ad&tab=core&_cview=1)
- Record
- SN01770789-W 20090319/090317215717-08c02f44974230ed6180fd62336c5397 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |